TORONTO, ON / ACCESSWIRE / January 30, 2017 / Mag Copper Limited (CSE: QUE) (the “Company”) announces that it has filed articles of amendment giving effect to the consolidation of its issued and outstanding common shares (“Common Shares”) on a one (1) for five (5) basis (the “Consolidation”).

The Consolidation was approved by shareholders at the annual and special meeting held on June 21, 2016. Subject to final confirmation by the Canadian Securities Exchange (the “CSE”), it is expected that the post-Consolidation Common Shares will begin trading on the CSE on or about February 2, 2017 under its current symbol “QUE”.

The Consolidation will reduce the number of outstanding Common Shares from 23,947,516 to approximately 4,789,503. Proportionate adjustments will be made to the Company’s outstanding stock options. No fractional Common Shares will be issued pursuant to the Consolidation and any fractional shares that would have otherwise been issued have been rounded down to the nearest whole number.

Letters of transmittal with respect to the Consolidation are being mailed to the Company’s registered shareholders. All registered shareholders will be required to send their share certificates representing pre-Consolidation Common Shares, along with a properly executed letter of transmittal, to the Company’s registrar and transfer agent, Capital Transfer Services Inc. (the “Transfer Agent”), in accordance with the instructions provided in the letter of transmittal. Shareholders who hold their Common Shares through a broker, investment dealer, bank, or trust company should contact that nominee or intermediary for assistance in depositing their Common Shares in connection with the Consolidation.

The Company would also like to announce the resignations of Terry Loney, John Carter, and Dan Weir. The board of directors and management of the Company would like to thank Messrs. Loney, Carter, and Weir for their contributions and wish them every success in their future endeavours.

Lisa McCormack has been elected to the board of directors. Ms. McCormack is currently Corporate Secretary of Barkerville Gold Mines Ltd. Prior thereto, Ms. McCormack served as Corporate Secretary of Kerr Mines Inc. from December 2013 to July 2016, Vice-President, Legal of Northern Gold Mining Inc. from October 2012 to June 2013, Corporate Secretary of Trelawney Mining and Exploration Inc. from January 2011 to June 2012, and Corporate Securities Law Clerk with Irwin Lowy LLP from August 2006 to December 2010 and from September 20, 2013 to present.

For more information, please contact:

Chris Irwin, President
Mag Copper Limited
T:(416) 361-2516
www.mag-copper.com

The Canadian Securities Exchange has not reviewed this press release and does not accept responsibility for the adequacy or accuracy of this news release.

This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

SOURCE: Mag Copper Limited

ReleaseID: 453821

PASADENA, CA / ACCESSWIRE / January 30, 2017 / Brazil Minerals, Inc. (OTC PINK: BMIX) (the “Company” or “Brazil Minerals”) announced today that one of its subsidiaries purchased a large centrifugal concentrator, which will be installed this week in an otherwise completed gold and diamond modular recovery plant, located in one of its mining concessions in the Jequitinhonha River valley in Brazil. The installation of this final piece of equipment will allow daily gold and diamond production to resume. As described in prior releases, the initial gold retrieval unit (GRU) built and used in the fourth quarter of 2016 could only process fine, sandy material for gold which had been filtered by manual processing. Later, with the addition of three additional machines, each involved in a specific separation step, the GRU was greatly upgraded to directly process thicker alluvial material, which normally has much higher concentration of gold and diamonds. The final step in the gold recovery of this new plant is separation by centrifugation, now addressed with the acquisition just made. It is anticipated that in its final format, this modular plant will eventually have two centrifuges to double throughput. A photograph of the actual initial centrifuge acquired is available below.

The factory that built the acquired centrifuge has been in business for over twenty years and has delivered centrifugation machines to multiple gold recovery plants in Brazil, Guyana, Paraguay, Peru, and Suriname. A photograph of a gold recovery plant in Brazil that uses several of such centrifuges in parallel is found below. Brazil Minerals believes that the approach in utilizing a modular plant structure for which the final step in gold recovery is executed by centrifugation will lead to higher yields and lower costs.

In other news, a qualified geologist has started to prepare an Industry Guide 7 technical report on the properties owned by Brazil Minerals. This study will permit the Company to publish information on all of its gold and diamond potential to the U.S. markets, as the Industry Guide 7 format is the reporting standard currently acceptable by the U.S. Securities and Exchange Commission (the SEC). As described in prior filings with the SEC, currently only a portion of one of the multiple mining concessions and other properties for gold and diamonds owned by Brazil Minerals has a technical report, and such report is in the NI 43-101 format used in Canada.

Additionally, the Company detailed in a Current Report on Form 8-K (8-K) filed with the SEC on January 27, 2017 that a 1-for-500 reverse split of its common stock has taken place. The 8-K can be accessed from the SEC’s website at www.sec.gov. For twenty trading days following the date of the reverse split, January 27, 2017, the Company’s common stock ticker symbol will be BMIXD. After that period, the ticker symbol will once again be BMIX. Following the reverse stock split, every 500 shares of common stock were converted into one share of new common stock. No fractional shares were issued with the reverse split. Any fractional shares that may potentially have resulted from the reverse split were rounded up to the nearest whole share. It is not necessary for stockholders to exchange their existing stock certificates for new stock certificates. Stockholders who hold their shares in brokerage accounts are not required to take any action to exchange their shares.

The reverse split was implemented for several reasons. One of them was to increase broker availability. The Company had been informed of shareholders being unable to buy and/or trade shares at multiple brokerage firms due to the low stock price prior to the reverse split. In addition, Brazil Minerals plans to up-list and/or possibly dual list with another jurisdiction, and for any of these a lower share count and higher share price are needed. Of note, following the reverse split, the Board of Directors has authorized the Company to effect a needed increase in authorized shares to replenish its reserves for issuance as compensation in lieu of cash, and for other uses; however, no acquisitions or other such expenditures are expected in the foreseeable future.

About Brazil Minerals, Inc.

Brazil Minerals, Inc. (OTC PINK: BMIX) is a producer of diamonds, gold, sand, and industrialized mortar. Through various subsidiaries, consolidated in our financial statements, we have title to 38 mineral rights for gold, diamonds, manganese, and sand, including 10 mining concessions for gold and diamonds, the highest level of right to mine in Brazil; the total surface area of these mineral rights is 218,525 acres or 440 square miles. More information on BMIX is at www.brazil-minerals.com.

Safe Harbor Statement

This press release contains forward-looking statements made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are based upon the current plans, estimates, and projections of Brazil Minerals, Inc.’s management and are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Such statements include, among others, those concerning market and industry segment growth and demand and acceptance of new and existing products; any projections of production, reserves, sales, earnings, revenue, margins, or other financial items; any statements of the plans, strategies, and objectives of management for future operations; any statements regarding future economic conditions or performance; uncertainties related to conducting business in Brazil, as well as all assumptions, expectations, predictions, intentions, or beliefs about future events. Therefore, you should not place undue reliance on these forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: business conditions in Brazil, general economic conditions, geopolitical events and regulatory changes, availability of capital, BMIX’s ability to maintain its competitive position and dependence on key management. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Contact:

Peter K. Goldy
Director of Communications
Brazil Minerals, Inc.
(213) 590-2500
info@brazil-minerals.com
www.brazil-minerals.com

SOURCE: Brazil Minerals, Inc.

ReleaseID: 453819

RADNOR, PA / ACCESSWIRE / January 30, 2017 / The law firm of Kessler Topaz Meltzer & Check, LLP alerts Vista Outdoor Inc. (NYSE: VSTO) (“Vista” or the “Company”) shareholders that a class action lawsuit has been filed on behalf of purchasers of the Company’s securities between August 11, 2016 and January 13, 2017, inclusive (the “Class Period”).

Shareholders who wish to discuss this action and their legal options are encouraged to contact Kessler Topaz Meltzer & Check, LLP (Darren J. Check, Esq., D. Seamus Kaskela, Esq. or Adrienne O. Bell, Esq.) at (888) 299-7706 or at info@ktmc.com.

Vista shareholders who purchased securities during the Class Period may, no later than March 27, 2017, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this action please visit https://www.ktmc.com/new-cases/vista-outdoor-inc#join.

Vista designs, manufactures and markets consumer products in the outdoor sports and recreation markets. Vista operates in two segments, Shooting Sports and Outdoor Products.

As detailed in the complaint, on January 11, 2017, Vista issued a press release entitled “Vista Outdoor Announces Expected Non-Cash Intangible Asset Impairment Charge.” Therein, Vista disclosed that it expected to record a material asset impairment charge in its Hunting and Shooting Accessories reporting unit in the third quarter of its fiscal year 2017 (“FY17”). Further, although Vista reported that it was still “in the process of finalizing the actual amount of the impairment, the Company’s preliminary analysis indicates the impairment charge will be in the range of $400 million to $450 million.” On this news, shares of the Company’s stock fell $8.21 per share, or 21.7%, to close on January 12, 2017 at $29.58 per share.

Then, on January 13, 2017, Vista disclosed that it had appointed a new President of its Outdoor Products segment. On this news, shares of the Company’s stock declined an additional $0.88 per share, or 3%, to close on January 13, 2017 at $28.70 per share.

The complaint alleges that, throughout the Class Period, the defendants failed to disclose: (1) that Vista was experiencing an acceleration in the softening of the retail environment and an acceleration in its own promotional activity; (2) that, as such, Vista was experiencing both revenue and gross margin declines; (3) that, as a result of the foregoing, the Company would have to begin the impairment assessment for its Outdoor Products segment’s reporting units in the third quarter of 2017, rather than with the preparation of the company’s FY17 annual financial statements; and (4) that, as a result, the Company would have to recognize an impairment charge in the range of $400 million to $450 million. The complaint further alleges that, as a result of the foregoing, the defendants’ statements about Vista’s business, operations and prospects were false and misleading and/or lacked a reasonable basis.

Vista shareholders may, no later than March 27, 2017, petition the Court to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. For additional information, or to learn how to participate in this action, please visit https://www.ktmc.com/new-cases/vista-outdoor-inc#join

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP

Darren J. Check, Esq.

D. Seamus Kaskela, Esq.

Adrienne O. Bell, Esq.

280 King of Prussia Road

Radnor, PA 19087

(888) 299-7706

(610) 667-7706

info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 453717

LOS ANGELES, CA / ACCESSWIRE / January 30, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against PayPal Holdings, Inc. (“PayPal” or the “Company”) (NASDAQ: PYPL), eBay Inc. (“eBay”) (NASDAQ: EBAY), and certain of its officers concerning possible violations of federal securities laws.

Investors who (1) purchased or otherwise acquired eBay securities on the open market on or after December 19, 2013 (“eBay Class Period”) and then received PayPal securities pursuant to eBay’s spin-off of PayPal, effective as of July 17, 2015; and/or (2) purchased or otherwise acquired PayPal securities on the open market between July 20, 2015 and April 28, 2016, both dates inclusive (the “PayPal Class Period” and, together with the eBay Class Period, the “Class Period”), are advised to contact the firm prior to the February 27, 2017 lead plaintiff deadline.

To participate in this class action lawsuit, call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

PayPal is a technology company that offers digital and mobile payment transactions between merchants and customers. Between 2002 and 2015, PayPal was a subsidiary of eBay. eBay is an e-commerce company that offers consumer-to-consumer and business-to-consumer purchases and payments.

Venmo is a mobile payment tool that allows users the opportunity to exchange payments from their bank accounts through their mobile phones.

The Complaint alleges that during the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: PayPal’s Venmo service was allegedly participating in unfair trade practices; the announcement of the above allegations was likely to affect PayPal’s profit on its Venmo service and/or thus, PayPal’s public statements were materially false and misleading at all relevant times.

On April 28, 2016, PayPal Holdings Inc. announced that federal regulators are investigating its Venmo service regarding possible unfair trade practices after receiving a civil investigative demand on March 28 from the Federal Trade Commission (the “FTC”) for Venmo documents. The FTC inquiry focuses on whether PayPal, through Venmo, participated in unfair or deceptive trade practices. The investigation “may result in substantial costs, including legal fees, fines, penalties and remediation expenses and actions, and require us to change aspects of the manner in which we operate Venmo.”

When this information was revealed to the investing public, the value of PayPal stock dropped $0.89 per share and closed at $39.18 on April 29, 2016, causing investors harm.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com

SOURCE: Lundin Law PC

ReleaseID: 453808

LOS ANGELES, CA / ACCESSWIRE / January 30, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Zimmer Biomet Holdings, Inc. (“Zimmer” or the “Company”) (NYSE: ZBH) concerning possible violations of federal securities laws between September 7, 2016 and October 31, 2016 inclusive (the “Class Period”). Investors, who purchased or otherwise acquired Tenet shares during the Class Period, are encouraged to contact the firm in advance of the January 31, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

Per the complaint, during the Class Period, Zimmer made materially false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects. The complaint is as follows: that issues within the supply chain caused a decline in order fulfillment, particularly within the knee and hip portfolios; that, because of this, Zimmer would not achieve its revenues and profit as anticipated; and, that as a result of the above, the Company’s statements regarding its business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

On October 31, 2016, the Company issued a press release reporting third quarter 2016 financial results. Zimmer reported net sales of $1.83 billion, and lowered guidance for the full year 2016 at $7.630 billion to $7.650 billion, a decline from the $7.68 billion to $7.715 billion estimated in July. Zimmer maintains that weak sales are due to a change in the supply chain, leading to a lack of available implants and instrument sets during the quarter.

In a conference with investors following the above release, the Company stated: “Third quarter revenue was below our expectations, primarily due to execution issues within our large joint supply chain, which led to a degradation in order fulfillment rates late in the quarter, as well as our performance in dental… As a consequence, we underestimated demand for certain key cross-sell brands within our existing customer base, leading to a depletion of our safety stocks and also affecting our ability to capitalize on new customer opportunities.”

Following this, shares of Zimmer fell $17.15 per share, or nearly 14%, to close on October 31, 2016 at $105.40 per share, causing investors serious harm.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com

http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 453806

IRVINE, CA / ACCESSWIRE / January 30, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Illumina, Inc. (“Illumina” or the “Company”) (NASDAQ: ILMN). Investors, who purchased or otherwise acquired shares between July 26, 2016 and October 10, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the February 15, 2017 lead plaintiff motion deadline.

If you purchased shares of Illumina during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that during the Class Period, Illumina made materially false and misleading statements regarding the Company’s business, operations, and prospects. In particular, Illumina made false and/or misleading statements and failed to disclose: that the Company was experiencing a sharp decrease in sequencing instrument sales; that the decline had a significant impact on the Company’s revenue; that the Company did not have visibility into trends that could have an impact on the Company’s financial outcomes; that, as such, the Company’s revenue guidance was unreliable and exaggerated; and that, as a result of the above, Illumina’s statements about the Company’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis. When this information was revealed to the public, the value of Illumina fell, causing investors serioius harm.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 453807

BURNABY, BC / ACCESSWIRE / January 30, 2017 / Bayhorse Silver Inc. (TSX-V: BHS) (the “Company” or “Bayhorse”) has received favorable initial test results from testing run-of-mine silver mineralization from the Bayhorse Mine, Oregon, USA., submitted to Steinert US, manufacturer of state-of-the-art Ore-Sorting equipment.

The Steinert X-Ray Transmission Ore-Sorter (XSS) effectively identified and discriminated between mineralized and non-mineralized silver bearing material, as well as differentiating higher (above 93 g/t or 3oz/t Ag) from lower (below 93 g/t or 3oz/t Ag) grade mineralization. The XSS rejected 37% from the stream as non mineralized and retained 63% of the run-of-mine stream. The material was sized between 1 inch (25mm) and 4 inches (100mm), and was comprised of high grade, low grade, and non-mineralized material.

Cannot view this image of the Steinert X-Ray Transmission Ore-Sorter?
Please visit [https://www.accesswire.com/uploads/Bayhorse_1.30.2017.jpg] to view this image.

Steinert X-Ray Transmission Ore-Sorter

The Company will be shipping a larger, approximately 2 ton, sample of the Bayhorse mineralized material to Steinert US to establish the crush size for the most effective sorting and rejection of unmineralized and lower grade (under 93 g/t or 3 oz/t Ag) material. The XSS is designed to sort material at up to 60 tons per hour from material sized at 10 mm (0.35 inch) to 200 mm (8 inches). By narrowing the size range for Ore-Sorting to between 12.5 mm (0.5 inch) to 32.5 mm (1.25 inch) and lowering the hourly throughput, the XSS can achieve better discrimination between low grade and the higher grades, and more effectively upgrade the mineralization.

Bayhorse CEO, Graeme O’Neill, comments, “By using the XSS, we could increase the proposed daily tonnage throughput from 100 tons/day to 150 tons/day with no other changes to the current in-place crushing-upgrading circuit. As the XSS uses no water and has a low power consumption requirement, we believe its use could have a substantial effect in reducing processing costs and increasing recoverable mineralization.”

He also notes that Adam Hamilton, of Zeal Research, has an article posted on 321Gold.com discussing silver’s potential upside in 2017: http://www.321gold.com/editorials/hamilton/hamilton012717.html

This News Release has been prepared on behalf of the Bayhorse Silver Inc. Board of Directors, which accepts full responsibility for its contents. On Behalf of the Board, Dr. Clay Conway, P.Geol., a Qualified Person and Director of the Company has prepared, supervised the preparation of, or approved the technical content of this press release.

Graeme O’Neill, President, 604-684-3394

Bayhorse Silver Inc., a junior exploration company, is earning an 80% interest in the historic Bayhorse Silver Mine, Oregon, USA. Bayhorse is also earning a 75% interest in the past producing Bridging the Gap Project, consisting of ASARCO’s historic Crown Point, Silver King, Ranger, Wyoming, Curlew, and Blackhawk silver/lead/zinc mines in Idaho’s Silver Valley. The Company has an experienced management and technical team with extensive exploration and mining expertise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Bayhorse Silver Inc.

ReleaseID: 453818

NEW YORK, NY / ACCESSWIRE / January 30, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired shares of Ophthotech Corporation (“Ophthotech”) (NASDAQ: OPHT) between May 11, 2015 and December 12, 2016. You are hereby notified that Levi & Korsinsky has commenced the class action Micholle v. Ophthotech Corporation, et al. (Case No. 1:17-cv-00210) in the USDC for the Southern District of New York. To get more information, go to: http://zlk.9nl.com/ophthotech, or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the Class Period, Ophthotech made overtly positive representations about the effectiveness and potential of its treatment Fovista when used in combination with Lucentis, a commercially available anti-vascular endothelial growth factor agent, despite awareness that the phase 3 clinical trial of Fovista would fail to achieve its primary endpoint of change in best corrected visual acuity from baseline at 12 months over Lucentis alone. The complaint further alleges that these statements caused Ophthotech stock to trade at artificially inflated prices.

On December 12, 2016, Ophthotech announced that the trial had failed to achieve its primary endpoint, and that Fovista and Lucentis demonstrated a non-statically significant improvement over patients only receiving Lucentis. Following this news, shares of Ophthotech fell approximately 86% to close at $5.29.

Take Action: if you suffered a loss in Ophthotech, you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 453816

NEW YORK, NY / ACCESSWIRE / January 30, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Agile Therapeutics, Inc. (“Agile Therapeutics”) (NASDAQ: AGRX) between March 9, 2016 and January 3, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information, go to: http://www.zlk.com/pslra/agile-therapeutics-inc, or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the Class Period, Agile Therapeutics made materially false and/or misleading statements and/or failed to disclose that: (a) the Twirla contraceptive patch had an efficacy rating that fell below peer group standards; (b) over half of patients in its “Secure” Phase 3 Study discontinued the study early; and (c) the Twirla patch therefore allegedly had a slight chance of gaining approval by the U.S. Food and Drug Administration.

On January 3, 2017, Agile Therapeutics reported “positive top-line results” for the study, yet reported an efficacy measure that failed to meet the standard set by other approved contraceptive patches. In addition, more than 51% of subjects opted to discontinue the study. Upon this news, shares of Agile Therapeutics fell from a close of $5.70 per share on December 30, 2016, to a close of $2.63 per share on January 4, 2017.

If you suffered a loss in Agile Therapeutics, you have until March 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 453817

NEW YORK, NY / ACCESSWIRE / January 30, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Seattle Genetics Inc. (“Seattle Genetics”) (NASDAQ: SGEN) between October 27, 2016 and December 23, 2016.

You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Washington. If you purchased or otherwise acquired Seattle Genetics securities between October 27, 2016 and December 23, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/seattle-genetics-inc or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period, Seattle Genetics made false and/or misleading statements and/or failed to disclose that: (a) its product in development, vadastuximab talirine, presents a significant risk of fatal hepatoxicity; (b) as such, Seattle Genetics had overstated the viability of vadastuximab talirine as a treatment for acute myeloid leukemia; and (c) as a result, the Company’s statements were materially false and misleading at all relevant times.

On December 27, 2016, Seattle Genetics issued a press release announcing that the U.S. Food and Drug Administration had placed a clinical hold or partial clinical hold on several early stage trials of vadastuximab talirine.

If you suffered a loss in Seattle Genetics, you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 453814